You are here

Pacific Biosciences of California, Inc. Third Quarter 2017 Financial Results Call

MENLO PARK, Calif., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) will hold its quarterly conference call to discuss its Third Quarter 2017 Financial Results on Thursday, November 2, 2017, at 4:30pm Eastern Time.

The call will be webcast and may be accessed at Pacific Biosciences’ website at:  http://investor.pacificbiosciences.com/.

Date:  November 2, 2017

Time:  4:30pm ET

Listen via Internet:  http://investor.pacificbiosciences.com/

Toll-free:  888.366.7247

International:  707.287.9330

Audience Passcode: 3297738

Replay:  http://investor.pacificbiosciences.com

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences' products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences' technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.

Contact:  Pacific Biosciences
Trevin Rard
650.521.8450
ir@pacificbiosciences.com

Friday, October 20, 2017 - 18:21

More Headlines

New Algorithm Surveys Alterations in DNA and Millions of Points in the Human Genome
First Oral Drug Increases Activity of the Body’s Deficient Enzyme
Venous Thromboembolism and Other Risks to Be Evaluated in Postmarketing Studies
Researchers Recommend Increased Testing for Men
New Draft Guidance Seeks to Better Target Patient Needs
It’s All in How the Data Are Analyzed
Two Phase 3 Studies Met Endpoint of Complete Clearance of Lesions